CA
NZ
UK
AU
IND
US
Skye Bioscience, Inc. (NASDAQ: SKYE) is poised to strengthen its position in the healthcare market through the acquisition of Redx Pharma Limited. ThisMergeris designed to occur via a scheme of arrangement, contingent uponShareholderapproval from both companies. This acquisition not only facilitates growth but also …
Neumora Therapeutics, Inc. (NASDAQ: NMRA) announced significant leadership changes alongside its second-quarter financial results for the period ended June 30, 2026. Effective August 14, 2026, Joshua Pinto, Ph.D. Will step into the role of Chief Executive Officer, succeeding Paul L. Berns, who will assume …
OPKO Health (NASDAQ: OPK), Inc. has successfully secured an additional $125 million by amending its existing Note Purchase Agreement. This move enhances its financial flexibility, enabling the healthcare company to pursue further investment opportunities. This capital will contribute to future growth initiatives, especially as …
The shift is attributed to lowered costs associated with contract research and finance support. The company’s financial position also includes cash, cash equivalents, and marketable securities amounting to $79.4 million, providing necessaryLiquiditythrough the second quarter of 2027. This strengthened cash runway is important as …
Prestige Consumer Healthcare Inc. (NYSE: PBH) is set to experience a significant leadership shift with the upcoming retirement of Jeffrey Zerillo, who currently serves as Senior Vice President of Operations. His retirement is officially effective on August 14, 2026, as he informed the company …
LeonaBio, Inc. (NASDAQ: LONA) posted a net loss of $19.0 million for the quarter ending June 30, 2026, reflecting the financial impact of a strategic shift toward intensive research and development activity. The escalation in losses is directly tied to the company’s ramp‑up of …
Lifeward posted Q2 2026 revenue of $6.6 million, a 16% increase from the prior year, while cash rose to roughly $11 million after a $5.6 millionCapitalinfusion. The strongerTop Lineand expandedLiquiditygive investors confidence in the company’s execution and funding runway.
Mesoblast announced the conclusion of its Phase 3 trial targeting low back pain, a study that enrolled 350 participants. The news sparked a 9% jump in the company’s share price, a reaction that rippled through the Australian biotech segment and highlighted the market’s appetite …
The licensing arrangement delivered both an upfront cash injection and a stream of ongoingRoyaltypayments, which the company booked as revenue during the reporting quarter. Those royalty receipts, together with the cash payment, comprised the majority of the $6.3 million revenue total reported for the …
Enveric Biosciences (NASDAQ: ENVB) announced a second‑quarter net loss of $3.0 million, equating to a diluted loss per share of $0.76, while simultaneously generating $5.0 million of upfront gross proceeds from a private placement and an extra $1.5 million from exercised warrants. Cash on …
Please wait processing your request...